Every 8-K that Repligen (RGEN) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow RGEN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RGEN filings page.
Repligen Corporation reported strong Q2 2026 results and raised its full-year 2026 outlook while signing a definitive agreement to acquire BioLife Solutions. Q2 revenue was $204 million, up 12% as reported and 13% organic versus $182 million a year ago. GAAP income from operations was $14 million, roughly flat year-over-year, and GAAP diluted EPS was $0.09 compared with $0.26. On a non-GAAP basis, adjusted income from operations rose to $34 million from $22 million and adjusted diluted EPS increased to $0.54 from $0.37.
GAAP gross margin was 53.9% versus 51.0%, while adjusted operating margin improved to 16.7% from 12.0%, and adjusted EBITDA margin reached 21.4%. Cash, cash equivalents and marketable securities totaled $810 million at June 30, 2026. For full-year 2026, the company now guides total reported revenue to $813M–$835M (10%–13% growth; 10.5%–13.5% organic) and diluted adjusted EPS to $2.03–$2.09, with adjusted operating margin of 15.7%–16.0% and adjusted EBITDA margin of 20.6%–21.0%. Management describes the BioLife Solutions acquisition as accretive to revenue growth, margin and adjusted EPS.
Repligen Corporation agreed to acquire BioLife Solutions in a cash-and-stock transaction valuing BioLife at $31.00 per share, or approximately $1.5 billion of enterprise value. Each BioLife share will be converted into $11.25 in cash plus 0.1442 shares of Repligen, with no fractional Repligen shares issued.
The deal, unanimously approved by both boards and expected to close in the fourth quarter of 2026, will be executed via two merger subsidiaries, making BioLife a wholly owned Repligen unit. Closing is subject to BioLife stockholder approval, antitrust clearances including the HSR Act, SEC effectiveness of a Form S-4, Nasdaq listing of new Repligen shares, and customary accuracy of representations and absence of material adverse effects. Under specified circumstances BioLife may owe Repligen a $59 million termination fee, and the merger agreement includes a no-shop with superior-proposal and fiduciary-out exceptions.
Repligen highlights the transaction as expanding its cell therapy tools portfolio and recurring consumables revenue and projects at least $20 million of year-one cost synergies, rising to $30 million in year two, with accretion of at least $0.05 to adjusted EPS in year one and $0.25 in year two. Separately, Repligen reports preliminary second-quarter 2026 revenue growth of 12% reported and 13% organic, while BioLife preliminarily reports $28.5 million in Q2 revenue, up 21% from $23.4 million.
Repligen Corporation reported the results of its 2026 Annual Meeting of Stockholders. As of the March 16, 2026 record date, 56,399,274 common shares were outstanding, and 54,022,359 were represented in person or by proxy, establishing a quorum.
Stockholders elected nine directors, each receiving more votes “for” than “against.” They also ratified the appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, and approved, on a non-binding advisory basis, the compensation of the company’s named executive officers.
Repligen Corporation reported solid growth for the first quarter of 2026. Revenue reached $194.3M, up from $169.2M, a 15% increase, with 11% organic growth. GAAP diluted EPS rose to $0.15 from $0.10, while adjusted diluted EPS increased to $0.48 from $0.39.
GAAP gross margin was 55.7% and adjusted gross margin was 55.5%, with adjusted operating margin improving to 15.4%. Cash, cash equivalents and marketable securities totaled $785M at March 31, 2026. The company divested its non-core Polymem filtration business and launched a Transformation Office focused on margin expansion.
For full-year 2026, Repligen guides to adjusted revenue of $803M–$833M, implying 9%–13% reported and organic growth, and projects adjusted diluted EPS of $1.97–$2.05. Management also highlighted a new OEM partnership in China to expand local manufacturing access.
Repligen Corporation reported strong fourth-quarter and full-year 2025 results and issued upbeat 2026 guidance. Q4 2025 revenue reached $198 million, up 18% year over year (14% organic). Full-year 2025 revenue was $738 million, a 16% increase with 14% organic growth.
Profitability improved sharply. Full-year GAAP income from operations was $55 million versus a loss of $35 million in 2024, while GAAP net income was $48.9 million compared to a $25.5 million loss. Adjusted net income rose to $96.9 million, with adjusted diluted EPS of $1.71 versus $1.58.
Margins expanded, with 2025 GAAP gross margin at 52.3% and adjusted operating margin at 13.8%. For 2026, Repligen guides revenue of $810–$840 million (10–14% reported growth, 9–13% organic), adjusted operating margin of 15.1–15.5%, adjusted EBITDA margin of 20–20.5%, and diluted EPS of $1.93–$2.01. Cash, cash equivalents and marketable securities totaled $768 million at December 31, 2025.
Repligen Corporation filed an 8-K stating it announced financial results for the third quarter ended September 30, 2025. The company furnished the full text of the announcement as Exhibit 99.1, a press release dated October 28, 2025.
The information provided under Item 2.02 is furnished and is not deemed “filed” under Section 18 of the Exchange Act, nor incorporated by reference, except as expressly set forth by specific reference.
Repligen Corporation has appointed Violetta Hughes as Chief Accounting Officer, effective September 1, 2025, making her the company’s principal accounting officer. Chief Financial Officer Jason K. Garland will remain in his role, with more of his time directed toward corporate strategy, financial planning and analysis, capital markets and growth initiatives.
Hughes brings over 25 years of finance and accounting experience from prior chief accounting officer and controllership roles at Azenta, Akebia Therapeutics and AMAG Pharmaceuticals, with a background in financial governance and Sarbanes–Oxley compliance. Her compensation package includes a $395,000 annual base salary, a $150,000 signing bonus, an annual target bonus of up to 50% of base salary, and annual equity awards totaling $750,000 in restricted stock units and stock options that vest in equal installments over five years.